A retrospective analysis of the randomised, phase 3 20020408 study which evaluated panitumumab plus best supportive care (BSC) vs BSC alone found a significant improvement in patient outcomes in patients with wild-type KRAS exon 2 tumours compared with those who had mutant KRAS exon 2 tumours (Amado et al, 2008). The gene discussed is KRAS; the disease is neoplasm.